The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to fund up to $54.3 million to advance Moderna’s mRNA‑1018 H5 avian influenza vaccine into Phase 3 testing. The move follows earlier U.S. government contracts that were scaled back, and CEPI’s grant includes commitments on affordability and 20% allocation of production capacity for low‑ and middle‑income countries in a pandemic scenario. Moderna’s program is being advanced amid renewed concern over zoonotic H5 outbreaks. Industry observers note the decision underscores CEPI’s role as a bridge funder when national priorities shift, and it keeps mRNA platforms in pandemic preparedness conversations despite political controversy over federal support for mRNA technology earlier in the year.